Position in APGE
as of Mar 31, 2026
· filed Apr 20, 2026
Position Value
$2,447,663
+$1,152,125 QoQ
Shares Held
29,080
+69.4% QoQ
Ownership
0.038%
of shares outstanding
% of Portfolio
0.44%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 33%
Shared 31%
None 36%
Common Shares in APGE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Moody Aldrich Partners LLC holds $91,411,685 across 28 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ORKA |
Oruka Therapeutics, Inc.
|
101,411 | $9,651,284 | |
| 2 | LGND |
Ligand Pharmaceuticals Inc
|
28,160 | $8,901,094 | |
| 3 | PTGX |
Protagonist Therapeutics, Inc
|
59,601 | $7,305,890 | |
| 4 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
74,552 | $7,267,328 | |
| 5 | PRAX |
Praxis Precision Medicines, Inc.
|
19,066 | $6,383,106 | |
| 6 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
146,077 | $5,466,201 | |
| 7 | NKTR |
Nektar Therapeutics
|
64,135 | $4,477,264 | |
| 8 | CAPR |
Capricor Therapeutics, Inc.
|
177,754 | $4,280,316 |
All Filings in APGE
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,447,663 | 29,080 | Shares | Sole | 2026-04-20 | |
| 2025-12-31 | $1,295,538 | 17,164 | Shares | Sole | 2026-01-30 | |
| 2025-09-30 | $715,616 | 18,012 | Shares | Sole | 2025-10-21 | |
| 2025-06-30 | $939,477 | 21,632 | Shares | Sole | 2025-08-04 | |
| No filing history on record for this holder in this stock. | ||||||